PD-L1 can be used as a targeted site, as shown by Yin et al., with PD-L1 nanobody-encapsulated gefitinib and simvastatin liposomes to overcome EGFR T790M-associated drug resistance in non-small cell lung cancer (NSCLC) (Figure 7A) [224]. Here, CD274 is linked to non-small cell lung carcinoma.